Key Points
- Insider sale: Lauren Rusckowski Duprey sold 34,535 Takeda shares for approximately $640,279, reducing her direct ownership by 15.28% to 191,522 shares. She also sold 47,586 shares in August.
- Stock performance: Takeda shares opened at $18.71, near their 52-week high of $18.90, with a market capitalization of approximately $59.95 billion.
- Fundamentals and outlook: Takeda exceeded quarterly earnings and revenue expectations, while analysts maintain a consensus “Buy” rating after several recent upgrades.
Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Lauren Duprey sold 34,535 shares of the business's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the transaction, the insider directly owned 191,522 shares of the company's stock, valued at approximately $3,550,817.88. The trade was a 15.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Lauren Rusckowski Duprey also recently made the following trade(s):
- On Monday, August 10th, Lauren Duprey sold 47,586 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total value of $813,720.60.
Takeda Pharmaceutical Trading Up 0.6%
NYSE TAK opened at $18.71 on Wednesday. The firm has a market cap of $59.95 billion, a P/E ratio of 55.03 and a beta of -0.07. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The stock's 50-day moving average is $17.58 and its 200-day moving average is $17.19. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $7.50 billion for the quarter, compared to analysts' expectations of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. SHP Wealth Management bought a new stake in Takeda Pharmaceutical during the 4th quarter worth about $42,000. Harbour Investments Inc. grew its holdings in shares of Takeda Pharmaceutical by 300.3% in the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company's stock valued at $72,000 after acquiring an additional 3,460 shares in the last quarter. Manchester Capital Management LLC increased its position in shares of Takeda Pharmaceutical by 91.4% in the fourth quarter. Manchester Capital Management LLC now owns 4,649 shares of the company's stock valued at $72,000 after acquiring an additional 2,220 shares during the last quarter. Rockefeller Capital Management L.P. increased its position in shares of Takeda Pharmaceutical by 30.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company's stock valued at $81,000 after acquiring an additional 1,215 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in Takeda Pharmaceutical by 3,783.0% during the fourth quarter. TD Private Client Wealth LLC now owns 9,824 shares of the company's stock worth $153,000 after acquiring an additional 9,571 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have weighed in on TAK. Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Zacks Research raised shares of Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded shares of Takeda Pharmaceutical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Takeda Pharmaceutical presently has a consensus rating of "Buy".
Get Our Latest Report on TAK
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Japan. The company researches, develops, manufactures and markets prescription medicines and vaccines for patients and healthcare professionals around the world.
Takeda focuses on several therapeutic areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Ninlaro for multiple myeloma and Iclusig for certain blood cancers, along with other specialty medicines and vaccines.
Founded in Osaka in 1781, Takeda has grown from a traditional pharmaceutical distributor into an international biopharmaceutical company serving markets across Japan, North America, Europe and other regions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
